# UK Porcine Vaccines Market > UK Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.41% - **2024:** $ 72 Million - **2025:** $ 75.9 Million - **2035:** $ 128.52 Million - **Key Players:** Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR) **Report ID:** MRFR/Pharma/49051-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-porcine-vaccines-market-50808 --- ## Market Summary ## **UK Porcine Vaccines Market Overview** As per MRFR analysis, the UK Porcine Vaccines Market Size was estimated at 67.12 (USD Million) in 2024.The UK Porcine Vaccines Market Industry is expected to grow from 72(USD Million) in 2025 to 258 (USD Million) by 2035. The UK Porcine Vaccines Market CAGR (growth rate) is expected to be around 12.303% during the forecast period (2025 - 2035) **Key UK Porcine Vaccines Market Trends Highlighted** The UK Porcine Vaccines Market is witnessing significant trends driven by several factors. One of the key market drivers is the rising awareness of animal health, particularly in the pig farming sector, which is crucial for maintaining livestock productivity and reducing disease outbreaks. The UK government has emphasized biosecurity measures and vaccination protocols to tackle challenges such as African Swine Fever and other infectious diseases affecting swine. This focus on health standards has led to an increased adoption of vaccines among pig breeders. Opportunities in the market are expanding as advancements in vaccine technologies are being explored. The use of new adjuvants and delivery systems is enhancing vaccine efficacy and flexibility, attracting attention from both producers and researchers. Moreover, with the growing awareness around antibiotic resistance, there is a shift towards preventive healthcare in pigs, which further drives the demand for effective vaccines. In recent times, trends such as the promotion of welfare standards have come to the forefront. The UK’s commitment to high animal welfare standards aligns with the increasing demand for ethically produced food.  This trend influences farmers to adopt vaccination practices that ensure healthier pigs, thereby supporting sustainable livestock farming.Furthermore, the integration of digital technologies in monitoring vaccination protocols highlights another trend, pushing farmers to adopt more data-driven approaches managing their livestock health. As these trends evolve, they reflect a broader commitment in the UK towards enhancing animal welfare and productivity through effective vaccination strategies in the porcine sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **UK Porcine Vaccines Market Drivers** **Rising Concerns Over Animal Health and Welfare** In the UK, there has been a significant increase in the awareness of animal health and welfare standards over recent years, primarily driven by national policies promoting better farming practices. The UK government outlined its commitment to enhancing animal welfare through the Animal Welfare (Sentencing and Recognition of Sentience) Bill, reflecting a growing societal expectation for high standards in livestock health. This is relevant to the UK Porcine Vaccines Market Industry, as healthier animals lead to greater demand for vaccines which can prevent diseases and boost overall productivity. **Technological Advancements in Vaccine Development** Advancements in biotechnology and Research and Development (R&D) in vaccine formulations are revolutionizing the UK Porcine Vaccines Market Industry. The UK is home to several prominent biotechnology firms and research institutions, such as the University of Edinburgh, which collaborates on vaccine innovation. These advancements have been shown to enhance the efficacy of vaccines and reduce production time. According to recent data from the UK Veterinary Medicines Directorate, vaccines developed using modern technologies have shown an improvement in efficacy rates by more than 25% compared to traditional methods.This technological progression not only benefits animal health but also secures a competitive edge for UK pork producers in the global market. **Increasing Pork Consumption in the UK** The demand for pork and pork products in the UK has demonstrated a consistent growth trend, with consumer preferences shifting towards high-quality meat products. The Agriculture and Horticulture Development Board has reported that pork consumption in the UK has increased by 7% over the last five years, correlating with growing awareness of nutrition and health. This uptick in demand is anticipated to drive the UK Porcine Vaccines Market Industry as more producers seek to ensure animal health and maximize productivity through effective vaccination programs.Addressing the increased pork demand requires a robust vaccination strategy to prevent outbreaks that could threaten supply chains and consumer health. **Government Support for Livestock Disease Prevention** The UK government has implemented several initiatives aimed at supporting livestock disease prevention to protect the agricultural economy. Programs such as the 'UK Pig Health Improvement Programme' create frameworks for enhanced biosecurity measures, vaccination programs, and disease monitoring systems. The UK Department for Environment, Food and Rural Affairs reported that livestock diseases can cause economic losses exceeding 50 million per year in the pork sector alone.Such economic pressures catalyze the need for effective vaccines, making government initiatives crucial to driving growth in the UK Porcine Vaccines Market Industry as they provide funding and structure for large-scale vaccination efforts among pork producers. **UK Porcine Vaccines Market Segment Insights** **Porcine Vaccines Market Type Insights** The UK Porcine Vaccines Market has been experiencing a notable shift in its dynamics, particularly when examining the diverse types of vaccines available for use in swine health management. This market is characterized by a wide array of vaccine types, which include Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, and DNA vaccines. Each type plays a distinct and vital role in maintaining animal health and supporting the livestock sector. Inactivated vaccines, which are pivotal for providing immunity without causing disease, have garnered considerable traction due to their safety profile, particularly in breeding stock. Similarly, live attenuated vaccines, known for their strong immune response, are actively utilized in controlling viral infections among pigs, thereby reducing morbidity and mortality rates. Toxoid vaccines are also significant within the market as they help combat diseases caused by bacterial toxins, making them an essential tool for swine producers in safeguarding herd health. Recombinant vaccines, leveraging advanced biotechnology, offer targeted responses to specific pathogens, which are increasingly preferred by modern livestock operations looking for efficacy and safety. Conjugate vaccines have been recognized for their enhanced efficacy against encapsulated bacteria, providing prolonged immunity in swine populations. Meanwhile, DNA vaccines are emerging as a promising innovation, offering a novel approach to immunization that enhances the body’s immune response by introducing genetically engineered DNA, which is seen as a crucial development in response to evolving diseases. The segmentation of the UK Porcine Vaccines Market by type illustrates a landscape ripe with opportunities, as each vaccine type caters to different pathogens and health challenges faced by swine, thus driving the market growth. The emphasis on biosecurity and disease prevention in the UK livestock industry, alongside the government's commitment to supporting animal health through research and development, is further propelling advancements in vaccine technologies. The consolidation of these types showcases both the robust demand for comprehensive vaccination programs and the integration of modern methodologies aiming at sustainable and efficient pig farming practices. Overall, the categorization into various vaccine types not only highlights the specificity of treatment options available but also underscores the proactive measures necessary to uphold animal welfare and productivity in the UK’s porcine sector. As emerging trends also lean towards increasing vaccination rates and expanding the spectrum of available products, the market dynamics are expected to evolve, aligning with best practices in veterinary medicine and agricultural protocols. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Porcine Vaccines Market Disease Indication Insights** The UK Porcine Vaccines Market’s segmentation under Disease Indication encompasses various critical diseases that significantly impact swine production and health. One prominent disease is Porcine Epidemic Diarrhea (PED), which has led to severe economic losses in recent years due to its high transmissibility and mortality rates in young piglets. Porcine Reproductive and Respiratory Syndrome (PRRS) is another major concern, known for its capability to compromise herd immunity and cause reproductive failures.  The Swine Influenza virus poses additional challenges, often leading to weight loss and increased susceptibility to secondary infections, which can strain veterinary resources.Aujeszky's disease (AD) remains a notable infectious disease in the UK pig population, threatening animal welfare by causing neurological signs and respiratory issues. Additionally, Porcine Circovirus Associated Disease (PCVAD) affects growth rates and overall herd health, necessitating effective vaccination strategies. Each of these diseases highlights the importance of investing in vaccines to sustain the UK’s pig farming industry and underscores the opportunity presented by innovative vaccine solutions in driving growth within the UK Porcine Vaccines Market.. **Porcine Vaccines Market End-user Insights** The End-user segment of the UK Porcine Vaccines Market plays a crucial role in the overall landscape of animal health, focusing primarily on Veterinary Hospitals and Hog Production Farms. Veterinary hospitals are essential as they offer advanced medical care for pigs, helping to diagnose and treat various diseases, which is vital for maintaining herd health and reducing the incidence of vaccine-preventable diseases. These facilities often serve as the primary point for administering vaccines, thereby ensuring that animals are protected against prevalent pathogens.On the other hand, Hog Production Farms represent a significant part of the market, as they are directly involved in the rearing and management of pigs.  These farms emphasize biosecurity and vaccination programs to safeguard their stock, which is fundamental for maximizing productivity and profitability in the highly competitive pork industry. The rising demand for pork products in the UK fuels the need for effective vaccine strategies to ensure healthy livestock, presenting substantial opportunities for growth in this segment. Increased awareness about animal welfare and the economic advantages of disease prevention through vaccination further drives the importance of these end-users in shaping the market dynamics of the UK Porcine Vaccines Market. **UK Porcine Vaccines Market Key Players and Competitive Insights** The UK Porcine Vaccines Market is characterized by a dynamic and evolving competitive landscape, shaped by factors such as regulatory pressures, technological advancements, and the increasing demand for sustainable livestock practices. As swine health becomes integral to food safety and agricultural productivity, various companies are investing in innovative vaccine solutions to meet these challenges. The competitive environment is marked by the presence of established players as well as new entrants aiming to capture market share through effective marketing, strategic collaborations, and groundbreaking research and development initiatives.  The interplay of these elements suggests that companies engaged in the UK Porcine Vaccines Market must consistently adapt to market demands while also keeping pace with scientific advancements to maintain their competitive edge.Phibro Animal Health Corporation stands out within the UK Porcine Vaccines Market due to its strong commitment to research and development, which fuels the creation of innovative vaccine solutions designed specifically for swine. The company's experience in the animal health sector enhances its reputation, supporting its ability to respond to the specific health challenges faced by the UK swine industry.  Phibro's portfolio includes a range of vaccines that have demonstrated efficacy and safety, giving farmers confidence in their products. Additionally, Phibro's established distribution network and relationships with livestock producers across the UK further bolster its market presence, allowing for effective outreach and support to livestock producers. The company's focus on enhancing animal welfare and productivity through vaccination solutions positions it favorably within a competitive market, enabling Phibro to sustain strong customer loyalty.Valneva, another key player in the UK Porcine Vaccines Market, has made significant advances with its specialized vaccination technologies tailored to the unique needs of swine health.  The company is recognized for its development of innovative vaccine products aimed at mitigating diseases prevalent in pigs, helping producers maintain healthy herds and comply with industry regulations. Valneva benefits from a strategic market presence in the UK, strengthened by partnerships and collaborations that enhance its research capabilities and facilitate access to a broader customer base. Valneva's emphasis on clinical efficacy and safety through robust testing and regulatory compliance ensures that its vaccines resonate well with farmers.  Furthermore, the company periodically explores mergers and acquisitions to bolster its position in the market and enhance its product offerings, reflecting a proactive approach to sustaining growth in the competitive landscape of porcine vaccines in the UK. **Key Companies in the UK Porcine Vaccines Market Include** **UK Porcine Vaccines Market Industry Developments** Recent developments in the UK Porcine Vaccines Market have been notable, particularly with advancements in vaccine formulations and regulatory approvals. Companies like Zoetis and Merck Animal Health have continued to innovate, focusing on improving vaccine efficacy against prevalent diseases in swine populations. Noteworthy is the increasing collaboration among firms, with Valneva announcing partnerships in September 2023 aimed at enhancing their portfolio of vaccines tailored for porcine health. The market has also seen consolidation activity, with Elanco acquiring a small biotech firm in August 2023 to boost their research capabilities in immunology specifically for swine health, which indicates a trend toward strategic mergers to strengthen market positions. Furthermore, Vetoquinol has expanded its product line in the UK, reflecting a growing demand for effective porcine vaccines amidst ongoing challenges related to animal health regulations. Over the past two years, the rise in ASF outbreaks in the UK has driven investments and R&D initiatives, positioning the market for further growth as stakeholders aim to enhance biosecurity measures and vaccination strategies. The UK government's support for animal health innovation has also been instrumental in promoting advancements in the porcine healthcare sector. **UK Porcine Vaccines Market Segmentation Insights** ## Market Drivers ### Advancements in Vaccine Technology Innovations in vaccine technology are significantly impacting the porcine vaccines market. The development of novel vaccine formulations, such as subunit and DNA vaccines, appears to enhance efficacy and safety profiles. These advancements may lead to increased adoption rates among farmers, as they seek to protect their herds from diseases like Porcine Reproductive and Respiratory Syndrome (PRRS). The UK market is witnessing a shift towards more effective vaccination strategies, which could potentially increase the overall market size. As of 2025, the market is projected to grow at a CAGR of around 5%, driven by these technological advancements. ### Government Initiatives and Support Government initiatives aimed at improving animal health and welfare are likely to bolster the porcine vaccines market. The UK government has implemented various programs to support livestock health, including funding for research and development of vaccines. Such initiatives may encourage the adoption of vaccination protocols among pig farmers, thereby enhancing herd immunity and reducing disease outbreaks. The financial backing from government sources could lead to a more robust market environment, as stakeholders are incentivized to invest in effective vaccination solutions. This support is crucial for the long-term sustainability of the porcine vaccines market. ### Rising Demand for Safe Meat Products The increasing consumer awareness regarding food safety and quality is driving the porcine vaccines market. In the UK, there is a notable shift towards ensuring that meat products are free from harmful pathogens. This trend is likely to enhance the demand for effective vaccines that can prevent diseases in pigs, thereby ensuring the safety of pork products. The UK pork industry, valued at approximately £1.2 billion, is under pressure to maintain high standards of animal health. Consequently, the porcine vaccines market is expected to grow as producers seek to comply with stringent food safety regulations and consumer expectations. ### Increasing Incidence of Swine Diseases The rising incidence of swine diseases is a critical driver for the porcine vaccines market. Outbreaks of diseases such as African Swine Fever (ASF) and Porcine Epidemic Diarrhea (PED) have raised alarms within the UK pig farming community. These diseases not only threaten animal health but also have significant economic implications, potentially leading to substantial losses for farmers. As a result, there is a heightened urgency to implement vaccination programs to mitigate these risks. The porcine vaccines market is expected to respond positively to this growing concern, as farmers seek effective solutions to protect their livestock. ### Consumer Preference for Sustainable Practices The increasing consumer preference for sustainable farming practices is influencing the porcine vaccines market. UK consumers are becoming more conscious of the environmental impact of livestock farming, leading to a demand for practices that promote animal health and welfare. Vaccination is viewed as a critical component of sustainable farming, as it helps reduce the need for antibiotics and minimizes disease transmission. This shift in consumer attitudes may encourage farmers to invest in vaccination programs, thereby driving growth in the porcine vaccines market. The alignment of vaccination strategies with sustainability goals could enhance market dynamics. ## Future Outlook The [Porcine Vaccines Market](https://www.marketresearchfuture.com/reports/porcine-vaccines-market-7438) is projected to grow at a 5.41% CAGR from 2025 to 2035, driven by increasing disease outbreaks, advancements in vaccine technology, and rising demand for pork products. **New opportunities:** - Development of customized vaccine formulations for specific regional diseases. - Expansion of digital platforms for vaccine tracking and management. - Investment in research for novel adjuvants to enhance vaccine efficacy. By 2035, the porcine vaccines market is expected to achieve robust growth and innovation. ## Segment Insights ### By Type: Inactivated Vaccines (Largest) vs. Live Attenuated Vaccines (Fastest-Growing) In the UK porcine vaccines market, the distribution among various vaccine types reveals that Inactivated Vaccines hold the largest market share, favored for their efficacy and established use within the industry. Live Attenuated Vaccines, while having a smaller existing market presence, are rapidly gaining traction, particularly among progressive producers looking for innovative solutions to enhance swine health and productivity. Growth trends indicate a notable shift towards the adoption of Live Attenuated Vaccines, driven by advancements in vaccine technology and increasing awareness regarding animal welfare. The demand for effective disease control in livestock is stimulating the development of newer vaccine formulations, allowing these vaccines to become more accessible. Additionally, favorable regulatory frameworks facilitate the entry of novel vaccine types into the market, further accelerating this growth. Inactivated Vaccines (Dominant) vs. Live Attenuated Vaccines (Emerging) Inactivated Vaccines are characterized by their long-standing presence in the UK porcine vaccines market, known for their stability and safety. These vaccines are crucial in providing comprehensive immunization against prevalent diseases and have become a standard choice for many farmers. In contrast, Live Attenuated Vaccines represent a rapidly emerging sector, showcasing potential for robust immune responses through live but weakened pathogens. As the market moves toward more efficient disease control, the future of Live Attenuated Vaccines appears promising, propelled by ongoing research and development aimed at maximizing their efficacy and minimizing risks, thus contributing significantly to the overall progression of vaccine utilization in pig farming. ### By Disease Indication: PRRS (Largest) vs. PED (Fastest-Growing) In the UK porcine vaccines market, the distribution of market share among disease indications reveals PRRS as the largest segment. This condition affects reproductive and respiratory health in pigs, and its prevalence significantly drives the demand for effective vaccines. Other notable segments include PED, which while smaller in market share, has been gaining attention due to its increasing incidence in herds across the region. The presence of additional diseases like swine influenza, Aujeszky's disease, and PCVAD also contributes to the overall landscape of the market. Analyzing growth trends, PED emerges as the fastest-growing segment, spurred by rising awareness and proactive measures taken by farmers to mitigate outbreaks. The growth of the PRRS segment continues to be driven by ongoing research and development efforts aimed at improving vaccine efficacy. Furthermore, the overall push towards biosecurity and health management in pig farming fosters a positive environment for vaccine adoption, leading to innovations in formulation and delivery methods. PRRS (Dominant) vs. PED (Emerging) Porcine Reproductive & Respiratory Syndrome (PRRS) stands as the dominant segment in the UK porcine vaccines market due to its widespread impact on herd fertility and respiratory health. The presence of PRRS is a major cause for financial losses among swine producers, making effective vaccination essential. As vaccination programs are established and their success rates improve, PRRS vaccines are prioritized by farmers. On the other hand, Porcine Epidemic Diarrhea (PED) is considered an emerging segment, whose severity is characterized by rapid loss of fluids in infected piglets. Farmers are increasingly adopting preventive measures against PED, making it a focal point of intervention strategies. This duality of dominance and emergence highlights the evolving dynamics within the UK porcine vaccines market. ### By End-user: Hog Production Farm (Largest) vs. Veterinary Hospitals (Fastest-Growing) In the UK porcine vaccines market, the market share distribution shows that Hog Production Farms dominate the landscape, holding a significant portion of the overall market. Contributing to this dominance are factors like the increasing scale of pig farming and the heightened focus on herd health management. In contrast, Veterinary Hospitals, while smaller in share, are gaining importance as they cater to the growing demand for specialized and preventive veterinary care in porcine health. The growth trends in this segment are driven by the rising awareness of disease prevention and control in pig populations. As farmers strive for better animal health and production efficiency, the need for effective vaccination strategies intensifies. Furthermore, the Veterinary Hospitals segment is emerging as a vital player due to the increasing collaboration between these facilities and farm producers, which is fostering innovative approaches to vaccination and health management, thus indicating a promising upward growth trajectory. Hog Production Farm (Dominant) vs. Veterinary Hospitals (Emerging) Hog Production Farms represent the dominant end-user in the UK porcine vaccines market, characterized by their substantial operational scale and focus on maximizing productivity through advanced health management techniques. These farms invest significantly in health protocols, making vaccines a core component of their husbandry practices. Conversely, Veterinary Hospitals emerge as a growing sector within this market, reflecting a shift towards specialized care and greater demand for preventive health services. The synergy between hog production and veterinary expertise is fostering innovations in vaccine applications, reflecting an evolving landscape focused on enhancing the overall health of swine populations. ## Competitive Benchmarking The porcine vaccines market in the UK is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on sustainability. Key players such as Zoetis (US), Boehringer Ingelheim (DE), and Merck Animal Health (US) are actively pursuing strategies that emphasize research and development, aiming to introduce novel vaccines that address emerging health challenges in swine populations. This competitive environment is further influenced by the growing demand for high-quality animal health products, driven by consumer preferences for sustainably sourced meat and the need for enhanced biosecurity measures in livestock farming.In terms of business tactics, companies are localizing manufacturing processes and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that hold substantial influence. This dynamic fosters a competitive atmosphere where innovation and operational excellence are paramount, as firms seek to differentiate themselves in a crowded marketplace. In October Boehringer Ingelheim (DE) announced the launch of a new vaccine targeting Porcine Reproductive and Respiratory Syndrome (PRRS), a significant advancement in the fight against this prevalent disease. This strategic move underscores the company's commitment to addressing critical health issues in swine, potentially enhancing its market position by offering solutions that meet urgent veterinary needs. The introduction of this vaccine is likely to bolster Boehringer Ingelheim's reputation as a leader in porcine health solutions. In September Merck Animal Health (US) expanded its portfolio by acquiring a biotechnology firm specializing in vaccine development for swine. This acquisition is indicative of Merck's strategy to enhance its research capabilities and accelerate the development of innovative vaccines. By integrating advanced technologies and expertise, Merck aims to strengthen its competitive edge and respond more effectively to the evolving challenges faced by swine producers. In August Zoetis (US) launched a digital platform designed to provide farmers with real-time data on vaccine efficacy and animal health management. This initiative reflects a broader trend towards digitalization in the animal health sector, where data-driven insights are becoming increasingly vital for decision-making. By leveraging technology, Zoetis positions itself as a forward-thinking player, likely enhancing customer engagement and loyalty through improved service offerings. As of November the competitive trends in the porcine vaccines market are heavily influenced by digital transformation, sustainability initiatives, and the integration of artificial intelligence in product development. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances innovation and market responsiveness. Looking ahead, the competitive differentiation is expected to evolve from traditional price-based competition towards a focus on technological advancements, innovative solutions, and reliable supply chains, reflecting the industry's shift towards a more sustainable and efficient future. ## Recent News & Developments Recent developments in the UK Porcine Vaccines Market have been notable, particularly with advancements in vaccine formulations and regulatory approvals. Companies like Zoetis and Merck Animal Health have continued to innovate, focusing on improving vaccine efficacy against prevalent diseases in swine populations. Noteworthy is the increasing collaboration among firms, with Valneva announcing partnerships in September 2023 aimed at enhancing their portfolio of vaccines tailored for porcine health. The market has also seen consolidation activity, with Elanco acquiring a small biotech firm in August 2023 to boost their research capabilities in immunology specifically for swine health, which indicates a trend toward strategic mergers to strengthen market positions. Furthermore, Vetoquinol has expanded its product line in the UK, reflecting a growing demand for effective porcine vaccines amidst ongoing challenges related to animal health regulations. Over the past two years, the rise in ASF outbreaks in the UK has driven investments and R&D initiatives, positioning the market for further growth as stakeholders aim to enhance biosecurity measures and vaccination strategies. The UK government's support for animal health innovation has also been instrumental in promoting advancements in the porcine healthcare sector. ## Report Scope | MARKET SIZE 2024 | 72.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 75.9(USD Million) | | MARKET SIZE 2035 | 128.52(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.41% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR) | | Segments Covered | Type, Disease Indication, End-user | | Key Market Opportunities | Advancements in vaccine technology enhance disease prevention in the porcine vaccines market. | | Key Market Dynamics | Rising demand for innovative porcine vaccines driven by regulatory changes and evolving disease threats in the UK. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the market valuation of the UK porcine vaccines market in 2024?** A: The market valuation was $72.0 Million in 2024. **Q: What is the projected market valuation for the UK porcine vaccines market by 2035?** A: The projected valuation for 2035 is $128.52 Million. **Q: What is the expected CAGR for the UK porcine vaccines market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 5.41%. **Q: Which companies are considered key players in the UK porcine vaccines market?** A: Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, Ceva Santé Animale, Virbac, Heska Corporation, and Vetoquinol. **Q: What are the main types of vaccines in the UK porcine vaccines market?** A: Main types include inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. **Q: What was the market value of live attenuated vaccines in 2024?** A: The market value of live attenuated vaccines was $25.0 Million in 2024. **Q: What is the projected market value for inactivated vaccines by 2035?** A: The projected market value for inactivated vaccines by 2035 is $36.0 Million. **Q: Which disease indications are covered by the UK porcine vaccines market?** A: Disease indications include PED, PRRS, swine influenza, Aujeszky's disease, and PCVAD. **Q: What was the market value for PRRS vaccines in 2024?** A: The market value for PRRS vaccines was $20.0 Million in 2024. **Q: What is the expected market value for hog production farms by 2035?** A: The expected market value for hog production farms by 2035 is $92.52 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-porcine-vaccines-market-50808*